NNVC · XBRL financial data

Nanoviricides financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NNVC's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Research and development	6,115	5,785	6,392	5,437	5,549	4,708
General and administrative	2,630	2,329	2,551	3,079	4,043	3,599
Total operating expenses	8,744	8,114	8,943	8,516	9,592	8,306
Operating income (loss)	(8,744)	(8,114)	(8,943)	(8,516)	(9,592)	(8,306)
Interest expense	85	5	1	50	0	—
Other income (expense)	9	12	356	272	125	88
Net income (loss)	(8,822)	(8,107)	(8,589)	(8,294)	(9,467)	(8,219)
Earnings per share, basic USD per share	(0.81)	(0.70)	(0.74)	(0.70)	(0.63)	(0.41)
Earnings per share, diluted USD per share	(0.81)	(0.70)	(0.74)	(0.70)	(0.63)	(0.41)
Weighted average shares, basic thousands of shares	10,901	11,535	11,626	11,871	15,117	20,188
Weighted average shares, diluted thousands of shares	10,901	11,535	11,626	11,871	15,117	20,188

Fiscal years (NNVC's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	20,517	14,066	8,150	4,798	1,559	2,794
Total current assets	20,824	14,416	8,445	4,971	1,671	3,163
Property and equipment, net	9,085	8,694	8,107	7,512	6,834	6,401
Total assets	30,262	23,495	16,900	12,823	8,824	9,874
Accrued liabilities	24	46	144	262	26	38
Total current liabilities	351	413	534	1,359	1,307	1,191
Total liabilities	—	413	2,034	1,359	1,300	1,200
Accumulated deficit	(114,385)	(122,492)	(131,081)	(139,375)	(148,842)	(157,060)
Total stockholders' equity	29,911	23,082	14,866	11,464	7,518	8,683
Total liabilities and equity	30,262	23,495	16,900	12,823	8,824	9,874
Common shares outstanding (cover page) thousands of shares	11,515	11,592	11,746	14,677	17,431	25,525

Fiscal years (NNVC's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	(8,822)	(8,107)	(8,589)	(8,294)	(9,467)	(8,219)
Net cash from operating activities	(8,214)	(5,891)	(5,670)	(6,316)	(8,479)	(7,696)
Purchases of property and equipment	239	324	152	157	57	84
Net cash from investing activities	—	(324)	(152)	(157)	(57)	(84)
Proceeds from issuing common stock	—	—	—	—	5,296	1,909
Proceeds from issuing equity	—	—	—	117	203	—
Net cash from financing activities	15,261	(235)	(95)	3,120	5,296	9,016

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Tenax Therapeutics	118,000	0*	(14,150)*	37.4M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Aytu Biopharma	26,308	16,106*	4,406*	10.9M	—	Q4 FY26 10-KJun 30, 2026
Dyadic International	1,425	961	(1,818)*	36.4M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Kala Bio	229	not reported	(1,535)*	19.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Lexaria Bioscience	3,500	0	(1,635)*	24.8M	2.2 quarters	Q3 FY26 10-QMay 31, 2026
Curis	5,073	0	(9,646)*	2.1M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.